SEC Form 6-K Summary: GlaxoSmithKline plc
Business Context and Reporting Period
This filing is a Form 6-K Report of Foreign Issuer submitted by GlaxoSmithKline plc (GSK) for the period ending November 12, 2018. The document serves as a transaction notification regarding the acquisition of company shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions executed on November 9, 2018.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.611 per share.
- Transaction Volume: 16 Ordinary Shares per executive (comprising 8 partnership shares and 8 matching shares).
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly discloses routine equity compensation transactions for the reporting period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The document is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of shares acquired by each named executive (16 shares each) against the company's broader equity compensation plan disclosures.
- Confirm the transaction date of November 9, 2018, aligns with the company's trading windows and blackout periods.
- Note that this filing does not reflect the company's overall financial performance; refer to the most recent Form 20-F or quarterly earnings release for revenue and profit data.
- Identify the specific roles of the transacting individuals, including CEO Emma Walmsley, CFO Simon Dingemans, and other senior leadership.